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Electrochemotherapy is an antitumour treatment that utilises locally delivered electric pulses to increase cytotoxicity of
chemotherapeutic drugs. Besides increased drug delivery, application of electric pulses affects tumour blood ﬂow. The aim of
this study was to determine tumour blood ﬂow modifying effects of electrochemotherapy with cisplatin, its effects on tumour
oxygenation and to determine their relation to antitumour effectiveness. Electrochemotherapy of SA-1 subcutaneous tumours
was performed by application of electric pulses to the tumours, following administration of cisplatin. Tumour blood ﬂow
modifying effects of electrochemotherapy were determined by measurement of tumour perfusion using the Patent blue
staining technique, determination of tumour blood volume, and microvascular permeability using contrast enhanced magnetic
resonance imaging, and tumour oxygenation using electron paramagnetic resonance oximetry. Antitumour effectiveness was
determined by tumour growth delay and the extent of tumour necrosis and apoptosis. Tumour treatment by
electrochemotherapy induced 9.4 days tumour growth delay. Tumour blood ﬂow was reduced instantaneously and persisted
for several days. This reduction in tumour blood ﬂow was reﬂected in reduced tumour oxygenation. The maximal reduction in
partial oxygen pressure (pO2) levels was observed at 2 h after the treatment, with steady recovery to the pretreatment level
within 48 h. The reduced tumour blood ﬂow and oxygenation correlated well with the extent of tumour necrosis and tumour
cells apoptosis induced by electrochemotherapy with cisplatin. Therefore, the data indicate that antitumour effectiveness of
electrochemotherapy is not only due to increased cytotoxicity of cisplatin due to electroporation of tumour cells, but also due
to anti-vascular effect of electrochemotherapy, which resulted in reduced tumour blood ﬂow and oxygenation.
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Electroporation, i.e. application of electric pulses to the cells or
tissues, induces under suitable conditions reversible permeabiliza-
tion of cell membrane, thus facilitating entry into the cells of
nonpermeant or poorly permeant molecules (Mir and Orlowski,
1999). Electroporation is currently used to facilitate cellular uptake
of drugs, dyes, antibodies, and DNA (Mir, 2000). Some chemother-
apeutic drugs are also poorly permeant for the cell membrane, but
cytotoxic once reaching their intracellular targets. Cytotoxicity of
these drugs can be increased by electroporation (Mir and Orlowski,
1999; Rols et al, 2000; Sersa, 2000a).
Electrochemotherapy consists of application of electric pulses to
the tumours after drug administration. Increased cytotoxicity of
bleomycin and cisplatin by electroporation was demonstrated in
vitro on several rodent and human cell lines (Mir and Orlowski,
1999; Rols et al, 2000). In addition, good antitumour effectiveness
of electrochemotherapy was demonstrated in vivo on different
tumour models in animals (Sersa, 2000a). Electrochemotherapy
with either bleomycin or cisplatin is effective at very low drug
concentrations that without application of electric pulses, have
minimal or no antitumour effect. Since the drug concentration
used in electrochemotherapy is low, drug related side effects were
not recorded so far. Furthermore, electrochemotherapy was effec-
tive in clinical settings. Several clinical trials on electro-
chemotherapy with either bleomycin or cisplatin have demon-
strated its effectiveness in treatment of cutaneous and
subcutaneous tumour nodules of head and neck tumours, basal cell
carcinoma of the skin, malignant melanoma, and adenocarcinoma
(Mir et al, 1998; Heller et al, 2000; Sersa et al, 2000b). From 70 to
100% objective responses were obtained 4 weeks after the treat-
ment, with a high percentage of local tumour control.
Electroporation of the cells in tissue is apparently the basic prin-
ciple of the antitumour effectiveness of electrochemotherapy. This
was demonstrated by data on increased drug concentration in
the tumours and increased binding of cisplatin to DNA after appli-
cation of electric pulses (Belehradek et al, 1994; Cemazar et al,
1999). Furthermore, it was found that application of electric pulses
to the tumours and normal tissues induces profound and reversible
reduction in blood ﬂow (Ramirez et al, 1998; Sersa et al, 1999a;
Gehl and Geertsen, 2000; Gehl et al, 2002). Previous study has
shown that tumour blood ﬂow is further reduced in electroche-
motherapy with bleomycin (Sersa et al, 1999b). In that study it
was speculated that bleomycin after electroporation of tumours
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www.bjcancer.comseverely damages vasculature of the tumours and consequently
induces a cascade of tumour cell death by ceasing oxygen supply
to the cells. This presumption was supported by in vitro study,
demonstrating that electroporation highly increases sensitivity of
endothelial cells to bleomycin, whereas to cisplatin in lesser extent
(Cemazar et al, 2001).
The aim of this study was to determine tumour blood ﬂow
modifying effects of electrochemotherapy with cisplatin, its effects
on tumour oxygenation and to determine their relation to antitu-
mour effectiveness. For this purpose contrast enhanced magnetic
resonance imaging (MRI) and tumour staining with Patent blue
were used, as well as electron paramagnetic resonance (EPR)
oximetry.
MATERIALS AND METHODS
Drugs
cis-Diamminedichloroplatinum (II) (cisplatin) was obtained from
Bristol Myers Squibb (Vienna, Austria) as a crystalline powder
and dissolved in sterile H2O at a concentration of 1 mg ml
71.
Final concentration was prepared in Eagle’s minimal essential
medium (EMEM, Sigma Chemical Co., St. Louis, MO, USA) for
experiments in vitro or in 0.9% NaCl solution for experiments in
vivo. For each experiment, fresh solution of cisplatin was prepared.
Cells, tumours and animals
Murine ﬁbrosarcoma SA-1 (The Jackson Laboratory, Bar Harbour,
ME, USA) cells were used for the experiments. For the in vitro
studies, they were grown in EMEM supplemented with 10% foetal
calf serum (FCS; Sigma Chemicals St. Louis, MO, USA) in a humi-
diﬁed atmosphere at 378C containing 5% CO2. The cells were
routinely subcultured twice a week.
A/J mice, of both sexes, purchased from the Institute Rudjer
Boskovic (Zagreb, Croatia) were used for this study. They were
kept at constant room temperature (228C) with a natural day/night
light cycle in a conventional animal colony with food and water ad
libitum. Before the experiments, the mice were subjected to an
adaptation period of at least 10 days. The mice were 10–14 weeks
old at the beginning of the experiments, weighing 20–25 g.
Tumour cells were obtained from the ascitic form of the
tumours in mice, serially transplanted every 7 days. Solid subcuta-
neous tumours, located dorsolaterally or ventrally in mice, were
initiated by an injection of 5610
5 SA-1 cells in 0.1 ml 0.9% NaCl
solution. Six to 8 days after implantation, when tumours reached
approximately 40 mm
3 in volume mice were randomly divided
into experimental groups. Treatment protocols were approved by
the Department of Agriculture of the Republic of Slovenia No.
323-02-183/99. The ethical guidelines that were followed meet
the standards required by the UKCCCR guidelines (Workman et
al, 1998). For MRI and EPR oximetry, animals were anaesthetised
with a mixture of Domitor (1.0 mg kg
71 body weight; Pﬁzer
GmbH, Karlsruhe, Germany) and 10% ketamine (75.0 mg kg
71
body weight; Veyx-Pharma GmbH, Schwartzenborn, Germany)
administered i.p. During anaesthesia, body temperature was kept
at physiological values by a regulated heating pad on which the
mice were placed (Guymar T/pump, Linton Instruments, Norfolk,
UK).
In vitro electrochemotherapy protocol
To determine the survival of SA-1 cells to combined treatment
with cisplatin and electric pulses, 90 ml of a cell suspension
(2.2610
7 cells ml
71) was mixed with 10 ml of different stock
concentrations of cisplatin, as described previously (Sersa et al,
1995). One half of the mixture was exposed to eight electric pulses
(1000 V cm
71, pulse duration 100 ms, frequency 1 Hz) and the
other half served as a control for cisplatin treatment alone. The
ﬁnal cisplatin concentrations ranged from 0.5 to 400 mgm l
71.
The cells were incubated for 5 min after electroporation, and there-
after clonogenic assay was performed (Sersa et al, 1995). The
survival of cells treated with combination of electric pulses and
cisplatin was normalized to electric pulse treatment alone. The
surviving fraction of cells treated with electric pulses alone was
0.85+0.1 (data not shown). The experiments were performed
twice, experimental groups in triplicates.
In vivo electrochemotherapy protocol
Cisplatin at a dose of 4 mg kg
71 was injected intravenously. Injec-
tion volume was 7.5 ml kg
71 body weight. Eight square-wave
electric pulses, delivered in two sets of four pulses in perpendicular
directions, of 1040 V amplitude (1300 V cm
71), with pulse width
of 100 ms and repetition frequency 1 Hz were delivered by two ﬂat,
parallel stainless-steel electrodes 8 mm apart (two stainless-steel
strips: length 15 mm, width 7 mm with rounded corners), which
were placed percutaneously at the opposite margins of the tumour.
Good contact between the electrodes and the skin was assured by
means of conductive gel. Electric pulses were generated by an elec-
troporator Jouan GHT 1287 (Saint Herblaine, France). In the
electrochemotherapy protocol, mice were treated with electric
pulses 3 min after cisplatin injection. All treatments were
performed without anaesthesia and were well tolerated by the
animals (Sersa et al, 1995).
Tumour growth was followed by measuring three mutually
orthogonal tumour diameters (e1,e 2 and e3) with a vernier caliper
three times per week. Tumour volumes were calculated by the
formula V=p6e16e26e3 /6. The arithmetic mean of tumour
volumes and standard error of the mean (s.e.) were calculated
for each experimental group. Tumour doubling time was deter-
mined for each individual tumour from the growth curves.
Tumour growth delay was calculated for each individual tumour
by subtracting the doubling time of each tumour from the mean
doubling time of the control group and then averaged for each
experimental group.
Assessment of tumour perfusion by Patent blue staining
Patent blue (Byk Gulden, Konstanz, Germany) was used to esti-
mate tumour perfusion. Patent blue (1.25 %) was injected
(0.2 ml) at different time points after treatment into the tail
vein of animals with tumours from control, electric pulses,
cisplatin and electrochemotherapy groups. After the dye was
distributed evenly through the tissue (1 min), animals were
killed by cervical dislocation which results in instantaneous
death of the animal and tumours excised, carefully removed
from the skin, cut in half along their largest diameter, and
immediately evaluated. The percentage of stained area for each
of the faces of the two halves of tumour cross-section
(perfused), as opposed to nonstained area (nonperfused) was
visually estimated by three individuals in blind fashion. The
mean of both estimations was used as an indicator of tumour
perfusion. Because of marked differences in tumour staining
between well-perfused and poorly perfused tumours, visual esti-
mation of the whole tumour cross-sections gives good
estimation and reliable results. In the study comparing Patent
blue staining and the pharmacological method (
86RbCl extrac-
tion technique) measuring relative tumour blood ﬂow, good
correlation between both methods was found (r=0.962) (Sersa
et al, 1999b). Brieﬂy,
86RbCl extraction technique gives measure
of tissue perfusion as a function of cardiac output and is
expressed as percent injected activity per gram or relative uptake
(per cent control) (Sapistein, 1958).
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An intermediate molecular size macromolecular magnetic reso-
nance contrast agent gadomer-17 (Shering AG, Berlin, Germany)
was used to assess changes in fractional tumour blood volume
(BV) and microvascular permeability surface area product (PS)
in control, electric pulses, cisplatin and electrochemotherapy trea-
ted animals. When administered i.v., this agent does not diffuse
through endothelium, unless there is a pathological change
(Demsar et al, 1997; Beravs et al, 2000). The size of the agent is
approximately 30 kDa, facilitating its complete renal elimination.
The agent was administered in a dose of 0.025 mmol kg
71 in a
bolus via 23-gauge intravenous cannula inserted into a tail vein
of anaesthetised mice. No systemic toxicity was observed. Animals
were placed in the 2.35 T Bruker Biospec system with a horizontal
bore magnet.
A pre-contrast image (complete k-space data set) was acquired
ﬁrst, using a standard spin-echo technique. Imaging parameters
were: repetition time, TR=600 ms; echo time TE=18 ms; matrix,
2566256; slice thickness, 2 mm; ﬁeld of view, 7 cm; and acquisi-
tion time 5 min. Second, gadomer-17 was administered, and a
central data subset of the k domain (in the phase-encoding direc-
tion) with dimensions 326256 k space data points was acquired
repetitively for 70 min (80–100 ‘key’ images). Each key image
was acquired with 32 phase-encoding steps that took 38 s. Before
the reconstruction, the subset was ﬁrst completed in remaining
k-space points (which were not included in temporal acquisition)
with the data from the pre-contrast acquisition. Finally, images
were reconstructed with two-dimensional inverse Fourier transfor-
mation.
To obtain a measure for altered blood ﬂow (PS and BV), the
magnetic resonance signal was measured within the tumour and
vena cava in pre-contrast image and at least 80 post-contrast
images that were acquired every 38 s. The signal was corrected
for signal variations against a water phantom. From the measured
signal, the concentration CT, of the gadomer-17 in the tumour was
calculated by subtraction of the pre-contrast signal from the post-
contrast signals on a pixel-by-pixel basis. The T1 relaxivity in water
Gd
71 at 20 MHz and 39 8C is 14.4 mmols
71 (Demsar et al, 1997).
The concentration of gadomer-17 in a slow-ﬂowing vessel, such as
the inferior vena cava, CB, was obtained in a similar way. The line-
arity of the CT/CB ﬁt was checked for the ﬁrst 30–50 points. PS
and BV were calculated using an established method (Demsar et
al, 1997). PS, which represents fraction of contrast agent leaking
out of the blood in time [% h
71] was calculated as:
PS  PS01 ÿ Hct
where Hct is the measured haematocrit of the blood (47% for
tumours in animals) and PS' is linear ﬁt coefﬁcient of CT/CB at
different time points. BV, which represents fraction of contrast
agent leaking through tumour endothelium into interstitial space
in time was calculated as:
BV 
CTt
CBt
ÿ PS0t
where CT is concentration of contrast agent in tumour and CB
concentration of contrast agent in blood.
EPR oximetry
EPR oximetry was used to evaluate changes in partial oxygen pres-
sure (pO2) in tumours and subcutis on the contralateral side before
and after treatment of tumours with electric pulses, cisplatin and
electrochemotherapy. EPR oximetry is a non-invasive method,
(after insertion of the paramagnetic probe) which allows monitor-
ing of pO2 repeatedly at the same point in the tissue over long
periods of time (O’Hara et al, 2001; Sersa et al, 2001). For this
purpose a paramagnetic probe, a char (0.5 mm
3, with particle size
10 mm) made from Bubinga tree (a kind gift of EPR centre for
viable system, Dartmouth College of Medicine, Hanover, NH,
USA), which is sensitive to oxygen was implanted into tumour
center and periphery (tumour volume approximately 40 mm
3)
and subcutis one day before the treatments and its EPR spectral
line-width measured at different time points up to two days after
treatment (Krzic et al, 2001). The char implantation with a sterile
needle did not provoke bleeding. In the presence of oxygen, the
line-width of the EPR lines is broadened; the extent of broadening
depends on pO2 (Swartz et al, 1993; Swartz and Clarkson, 1998).
The pO2 in the region in contact with the probe was measured.
The measurements were performed on a Varian E-9 EPR spec-
trometer, with a custom-made low-frequency microwave bridge
operating at 1.1 GHz and an extended loop resonator (11 mm in
diameter), both designed by Professor T Walczak (Dartmouth
Medical School, Hanover, NH). Typical spectrometer settings were:
modulation frequency, 100 KHz; modulation amplitude not more
than one-third of the peak-to-peak line-width, and scan range,
2 mT. The line width of the EPR spectra reﬂects the pO2, which
was determined from an existing calibration curve (Krzic et al,
2001).
Histology of tumours
The same tumours that were used for Patent blue staining were
ﬁxed in 10% buffered neutral formalin. Sections through the
largest diameter of the tumours were embedded in parafﬁn,
cut and stained with haematoxylin and eosin by standard meth-
od. Necrosis in slides of 3–9 tumours per group were
determined in blind fashion by three experts. The percentage
of necrotic area was determined in whole mount tumour
sections.
The apoptotic rate was determined using Cell Death Detection
ELISA (Boehringer Mannheim, Germany). The assay is based on
the quantitative sandwich-enzyme-immunoassay principle and
detects apoptotic cells relatively selectively even in the presence
of an excess of necrotic cells (Leist et al, 1995). This procedure
permits a speciﬁc determination of mono and oligonucleosomes
in the cytoplasmic fraction of cell lysates characteristic for apopto-
sis. Tumours used for determination of apoptosis were ﬁrst
squeezed between two sintered microscope slides. Then the suspen-
sion was washed and cells exposed to the lysing buffer. After lysis,
supernatant containing apoptotic bodies was prepared by centrifu-
ging the sample at 15000 r.p.m. In the ﬁrst step of ELISA
procedure, monoclonal anti-histone antibodies directed against
H2A, H2B, H3 and H4 histone antigens were ﬁxed to the wall
and the bottom of the microtiter plate module. During the second
step, the nucleosomes contained in the sample bind via their
histone components to the immobilised anti-histone antibodies.
In the third step, anti-DNA-POD antibodies reacted with the
DNA part of the nucleosome. The amount of peroxidase retained
in the immunocomplex was determined spectrophotometrically
with ABTS (2,2'-azino-di-(3-ethylbenzthiazoline sulphonate)), as
substrate. All the measurements were done in triplicates on six
mice per group.
Statistical analysis
All data were tested for normality of distribution using the Kolmo-
grov–Smirnov test. The differences between the mean values of
groups were tested for signiﬁcance by a t-test after one-way
ANOVA was performed and fulﬁlled. SigmaStat statistical software
(SPSS inc.) was used for statistical analysis. P levels of less than
0.05 were taken as signiﬁcant.
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Antitumour effectiveness
The cytotoxicity of cisplatin after electroporation of ﬁbrosarcoma
SA-1 cells was determined in vitro by a colony forming assay.
Exposure of cells to electric pulses resulted in a marked increase
in cisplatin cytotoxicity. Throughout the range of cisplatin concen-
trations investigated, cells exposed to electric pulses were more
sensitive to cisplatin than those that were not (Figure 1). The cells
exposed to electric pulses were 10-fold more sensitive to cisplatin
as determined at the concentration causing 50% inhibition of
colony formation.
Treatment of subcutaneous SA-1 tumours by electrochemother-
apy with cisplatin was very effective, resulting in substantial
tumour growth delay, compared to untreated tumours and
tumours treated with cisplatin or application of electric pulses only
(Table 1). Electrochemotherapy treatment induced a reduction of
tumour volume that was observable 3 days after the treatment.
Thereafter the tumours gradually reduced in size and by the 6th
day they had decreased to pretreatment values. Tumours were
neither ulcerated nor had a superﬁcial scab. Regrowth of tumours
started at the 7th day after the treatment. Their growth rate then
was approximately the same as in the control groups. The treat-
ment of animals with cisplatin or application of electric pulses to
the tumours as single treatment did not result in a substantial anti-
tumour effect.
Tumour blood ﬂow
The time course of tumour perfusion changes was evaluated in
untreated, tumours treated by cisplatin or application of electric
pulses only, and after electrochemotherapy. Application of electric
pulses to the tumours induced a signiﬁcant and rapid reduction in
tumour perfusion as measured by Patent blue staining (Figure 2).
Within 2 h tumour perfusion was reduced to 30%, but returned to
near the pretreatment value within 24 h. Thereafter the perfusion
was similar to the perfusion in untreated or cisplatin treated
tumours. Electrochemotherapy induced the same onset of tumour
perfusion changes as the application of electric pulses. Thereafter,
within 8 h tumour perfusion was restored to approximately 40%
of the pretreatment value where it remained up to the 5th day.
From the 8 h to the 5th day after the treatment with electroche-
motherapy, tumours were signiﬁcantly less perfused than
tumours treated with cisplatin or electric pulses only (Figure 2).
Dynamic contrast-enhanced MRI was used to evaluate changes
in tumour BV and PS 24 h after treatment with cisplatin, applica-
tion of electric pulses and after electrochemotherapy. The tumour
periphery was enhanced more than the centre of the tumour in
the ﬁrst minute after the injection of the contrast agent, indicating
that the periphery was better vascularised than the centre (data not
shown). The tumour enhancement increased gradually, indicating
diffusion of the contrast agent from the blood into the interstitial
space. Tumours treated with electrochemotherapy showed delayed
enhancement with gadomer-17, indicating a change in blood ﬂow
or decreased permeability. The concentration of contrast agent in
the tumour (CT) gradually increased over 70 min observation time
(Figure 3). The smallest reduction in contrast agent accumulation
was observed after treatment with cisplatin. Application of electric
pulses caused a moderate reduction in contrast agent accumula-
tion, which correlated with the observations of tumour perfusion
after Patent blue staining. Electrochemotherapy resulted in a larger
(2.5-fold) reduction in contrast agent accumulation. These obser-
vations were supported by calculated tumour BV and PS (Table 2).
Tissue oxygenation
EPR oximetry was used to measure pO2 in the tumours as well as
in subcutis. The pO2 values in normal subcutis
(8.37+0.05 mmHg) were higher than in the untreated tumour
tissue (Table 3). Within the untreated tumours, higher pO2 values
were measured in the tumour periphery (7.3 mmHg) than in the
tumour centre (5.3 mmHg).
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Figure 1 Potentiation of cisplatin cytotoxicity in vitro by electroporation
of SA-1 tumour cells. The clonogenicity of cells was determined after cis-
platin treatment for 5 min, exposure to electric pulses, or combination
of both (electrochemotherapy). The survival curve for the electroche-
motherapy treated cells was normalised for the cytotoxicity of electric
pulses treatment alone. Surviving fraction of cells treated with electric
pulses alone was 0.85+0.1. Symbols represent mean values+s.e. of
pooled data from two experiments done in triplicates.
Table 1 Antitumour effectiveness of electrochemotherapy on SA-1
tumours in mice
Tumour doubling Tumor growth
time (days; delay (days;
Therapy n mean+s.e.) mean+s.e.)
Control 18 1.8+0.1
Cisplatin
a 18 2.3+0.1 0.5+0.1
Electric pulses
b 18 2.6+0.1 0.8+0.1
Electrochemotherapy
c 18 11.2+1.4
d 9.4+1.4
aCisplatin injected i.v. (4 mg kg
71);
bApplication of electric pulses to the tumour (8
pulses, 1300 Vcm
71, 100 ms, 1 Hz).
cElectrochemotherapy: application of electric
pulses to the tumour 3 min after i.v. injection of cisplatin.
dP value (50.05) for elec-
trochemotherapy treatment vs other treatments.
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Figure 2 Time course of changes in tumour perfusion measured by Pa-
tent blue staining in untreated control tumours, after treatment of tumours
by application of electric pulses, cisplatin, or electrochemotherapy. Symbols
indicate mean values+s.e. of at least six mice per point.
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changes in tumour perfusion, as measured by Patent blue staining.
A very fast and profound reduction of pO2 was observed in the
tumours after application of electric pulses to the tumours and
after electrochemotherapy. The maximal reduction was observed
within 2 h after the treatment, with steady recovery thereafter.
The recovery to pretreatment levels was slower after electroche-
motherapy (48 h) than after application of electric pulses (8 h).
Treatment with cisplatin only and effects on subcutis, contralateral
to the application of electric pulses or electrochemotherapy had
only short lasting effects on pO2 (Table 3; Figure 4). Effects of
different treatments; cisplatin, electric pulses and electrochemother-
apy had only short lasting effects on pO2 in the contralateral
subcutis, with maximal reduction at 2h (7.35+0.13; 7.66+0.08;
6.80+0.1 mmHg, respectively).
Necrosis and apoptosis
The time course of tumour necrosis was evaluated for 5 days after
treatment. The extent of necrosis in the cisplatin treated tumours
was similar to the untreated tumours. Application of electric pulses
to the tumours induced a slow increase in tumour necrosis up to
8 h after treatment, and remained on this level up to the 5th day.
In electrochemotherapy treated tumours the degree of tumour
necrosis followed the onset of tumour necrosis in the group treated
with electric pulses only, and continued to increase up to the 3rd
day after the treatment, when it reached 90% and it remained at
this level through the 5th day (Figure 5). In the tumours treated
with electrochemotherapy irreversible cell injury also was shown
by conﬂuent areas of cells with distinct changes. Tumour cells were
swollen with picnotic nuclei. Perinuclear cytoplasm was condensed,
eosinophilic, and ﬁlled with multiple blebs at the periphery of the
cells. In electrochemotherapy treated tumours, in non-necrotic
tumour areas distinct apoptotic cells and apoptotic bodies were
noticed. Electrochemotherapy induced apoptosis in the tumours
was conﬁrmed by an ELISA assay. A statistically signiﬁcant fourfold
increase in apoptosis was observed 24 h after the treatment with
electrochemotherapy compared to untreated controls (Figure 6).
DISCUSSION
This study shows that electrochemotherapy with cisplatin reduces
tumour blood ﬂow instantaneously and persists for several days.
This reduction in tumour blood ﬂow was reﬂected in reduced
tumour oxygenation recovering to the pretreatment level within
two days. The time course of reduced tumour blood ﬂow and
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Figure 3 Time course of gadomer-17 accumulation in untreated control
tumours and tumours 24 h after treatment with cisplatin, application of
electric pulses, and electrochemotherapy. Two tumours were implanted
ventrally in mice. In one set of experiments one tumour served as control,
to the other electric pulses were applied. In the other set of experiments
mice were injected with cisplatin and one tumour also received electric
pulses (electrochemotherapy). Contrast agent was injected at time zero,
each group consisted of three mice; for simplicity error bars were omitted.
Table 3 Partial oxygen pressure (pO2) measured by EPR oximetry in SA-1 tumours and subcutis before and 2 h after the
treatment of tumours by electric pulses, cisplatin and electrochemotherapy. The data points were calculated from at least six
measurements per point.
Normal values Cisplatin
a Electric pulses
b Electrochemotherapy
c
Tissue/Therapy (mmHg, mean+s.e.) (mmHg, mean+s.e.) (mmHg, mean+s.e.) (mmHg, mean+s.e.)
Tumour periphery 7.33+0.09 5.96+0.29
d 2.16+0.07
d 1.66+0.07
d
Tumour center 5.35+0.05 4.60+0.28
d 2.68+0.14
d 1.60+0.04
d
aCisplatin injected i.v. (4 mg kg
71).
bApplication of electric pulses to the tumour (8 pulses, 1300 Vcm
71, 100 ms, 1 Hz).
cElectrochemotherapy:
application of electric pulses to the tumour 3 min after i.v. injection of cisplatin.
dP values (50.05) for different treatments vs normal values.
Table 2 Tumour blood volume (BV) and microvascular permeability
(PS) evaluated by dynamic gadomer-17-enhanced MRI in tumours 24 h
after treatment with cisplatin, application of electric pulses, and electroche-
motherapy
BV PS
Therapy n (% mean+s.e.) (% h
71, mean+s.e.)
Control 3 7.3+1.5 51.3+2.9
Cisplatin
a 3 6.4+0.2 47.2+1.5
Electric pulses
b 3 7.3+0.2 40.8+0.9
d
Electrochemotherapy
c 3 5.3+0.05 23.9+1.0
d
aCisplatin injected i.v. (4 mg kg
71).
bApplication of electric pulses to the tumour (8
pulses, 1300 Vcm
71, 100 ms, 1 Hz).
cElectrochemotherapy: application of electric
pulses to the tumour 3 min after i.v. injection of cisplatin.
dP values (50.05) for differ-
ent treatments vs control values.
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Figure 4 Time course of changes in partial oxygen pressure (pO2) mea-
sured by EPR oximetry in tumours (combined data for tumour centre and
tumour periphery) after the treatment of tumours by application of electric
pulses, cisplatin, or electrochemotherapy. Symbols indicate mean va-
lues+s.e. of six mice per point.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(9), 1047–1054tumour oxygenation correlated with time course of antitumour
effectiveness, tumour necrosis and apoptosis induced by electroche-
motherapy with cisplatin. Therefore, the data indicate that
antitumour effectiveness of electrochemotherapy is not only due
to increased cytotoxicity of cisplatin due to electroporation of
tumour cells, but also due to anti-vascular effect of electroche-
motherapy, which results in reduced tumour blood ﬂow and
oxygenation.
Increased cytotoxicity of the drugs by electroporation is the
predominant mechanism involved in antitumour effectiveness of
electrochemotherapy. This notion is supported by the data in vitro
demonstrating that exposure of tumour cells to electric pulses
increases cytotoxicity of bleomycin several 100-fold, and as in this
study, cisplatin cytotoxicity 10-fold (Jaroszeski et al, 2000). Among
several other known anti-neoplastic drugs that were tested, these
two drugs were shown to be the best candidates for electroche-
motherapy, because they are hydrophilic and have good
antitumour effectiveness once their access to cytosol is facilitated
by electroporation (Sersa et al, 1995; Mir and Orlowski 1999).
Presumption, that increased cytotoxicity of the drugs is the main
mechanism involved in antitumour effectiveness of electroche-
motherapy, is supported by the data demonstrating that
electroporation causes increased bleomycin as well as cisplatin
accumulation in the tumours (Belehradek et al, 1994; Cemazar et
al, 1999). Speciﬁcally, in SA-1 tumours, as used in this study,
the amount of platinum bound to DNA and platinum content in
the tumours treated by electrochemotherapy was approximately
two times higher compared to cisplatin treatment alone (Cemazar
et al, 1999). All these data support the notion that electroporation
either in vitro or in vivo is the predominant mechanism involved in
antitumour effectiveness of electrochemotherapy.
In view of our previous study, demonstrating that electroche-
motherapy with cisplatin induced more than a 20-fold increase
in cell kill in SA-1 tumours, compared with cisplatin treatment
alone, we proposed that, in addition to electroporation of tumour
cells that induces approximately 10-fold increase in cytotoxicity in
SA-1 cells in vitro, other mechanism may be involved in antitu-
mour effectiveness of electrochemotherapy (Cemazar et al, 1999).
Additional mechanisms involved in antitumour effectiveness of
electrochemotherapy with cisplatin were proposed: immune
response (Mir et al, 1992; Sersa et al, 1997), anti-vascular effect
due to cytotoxic action on endothelial cells (Cemazar et al, 2001)
and tumour blood modifying effect of electrochemotherapy (Sersa
et al, 1999b).
Electroporation is a universal process, therefore application of
electric pulses to solid tumours would be expected to increase
permeability of cell membrane of all cells that are treated. Potential
targets include endothelial cells lining the tumour vasculature.
Damage to endothelial cells may lead to obstruction of blood ﬂow
and ischaemic death of tumour cells lining the obstructed blood
vessel. This phenomenon, described as anti-vascular or vascular-
targeted therapy, gained high interest and has been exploited in
several studies (Chaplin et al, 1998; Denekamp et al, 1983). In
the ﬁrst step to conﬁrm that electrochemotherapy has an anti-
vascular effect, we determined in our previous study sensitivity
of human microvascular endothelial cells (HMEC-1) to bleomycin
and cisplatin, with and without in vitro electroporation of cells
(Cemazar et al, 2001). HMEC-1 cells were moderately sensitive
to continuous exposure to cisplatin, but showed greater sensitivity
to bleomycin. However, electroporation of cells increased cytotoxi-
city by *10-fold for cisplatin and *5000-fold for bleomycin.
The above mentioned is supported by the observations that elec-
trochemotherapy with bleomycin resulted in complete shut down
of tumour blood ﬂow observed by 12 h after the treatment, and
correlated with antitumour effectiveness and the extent of tumour
necrosis (Sersa et al, 1999b). In the present study, the antitumour
effectiveness of electrochemotherapy with cisplatin could also in
part be ascribed to its anti-vascular effect. Electrochemotherapy
induced signiﬁcant reduction in tumour perfusion, stabilizing at
40% pretreatment level up to the 5th day after treatment. The data
on contrast enhanced MRI support these observations, 24 h after
the electrochemotherapy tumours were signiﬁcantly less enhanced
than after the treatment with cisplatin or electric pulses.
Reduced tumour blood ﬂow is expected to result in lower
oxygen tension. By using EPR oximetry we were able to follow
the time course of oxygen tension in the tumours. Electroche-
motherapy induced profound and long lasting pO2 reduction,
which is expected to cause some additional cell kill in the tumours
due to the prolonged hypoxia. The onset and time course of
tumour oxygenation changes correlated with tumour blood ﬂow
reduction, and resulted in gradual increase in extent of tumour
necrosis, that reached approximately 90% of the tumour area, three
days after treatment. That coincided with the time when the
tumours started to reduce in the size and ceased to grow. The
tumours started to regrow only 7 days after the treatment. The
resulting antitumour effect was 9.4 days tumour growth delay,
which is signiﬁcantly better than the effect of single treatments,
cisplatin (0.5 days tumour growth delay) and application of electric
pulses (0.8 days tumour growth delay). The effect was less
pronounced than in electrochemotherapy with bleomycin, which
is consistent with in vitro data on endothelial cells sensitivity (Sersa
et al, 1999b; Cemazar et al, 2001).
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Figure 6 Time course of changes in apoptotis (O.D.) in the untreated
control tumours, and tumours after treatment by application of electric
pulses, cisplatin, or electrochemotherapy. Symbols indicate mean
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British Journal of Cancer (2002) 87(9), 1047–1054 ã 2002 Cancer Research UKThe proportion of apoptotic cells increased only after electro-
chemotherapy with cisplatin. Cisplatin is known to induce
apoptotic cell death, therefore it can be speculated that electroche-
motherapy, which increases cisplatin delivery into the cells, also
stimulates apoptotic cell death (Meyn et al, 1995; Jordan and
Carmo-Foncesca, 2000). In histological sections, apoptotic cells
were observed in non-necrotic regions, however necrotic regions
represented a major part in the sections of tumors treated with
electrochemotherapy, demonstrating that necrosis is a dominant
way of cell death induced by electrochemotherapy. In tumours
treated with cisplatin only apoptosis was not observed in the histo-
logical sections and also not detected by use of ELISA test for
determination of mono and oligonucleosomes in the cytoplasmic
fraction of cell lysates. The cisplatin dose used in experiments
was very low and is most probably the reason for the absence of
apoptosis. However, further studies are needed to fully understand
the mechanisms of cell death induced by electrochemotherapy with
cisplatin. It could be that higher amounts of cisplatin in the cells
combined with electroporation might more efﬁciently trigger
signalling pathways that lead to cell death. When response of the
tumours to electrochemotherapy using bleomycin or cisplatin is
compared macroscopically, tumours after electrochemotherapy
with cisplatin respond to the treatment much slower and usually
there is no ulceration of the tumours.
In conclusion, this study provides data on physiological changes
in the tumours, as a consequence of electrochemotherapy with
cisplatin and correlates these effects with antitumour effectiveness
and histological changes in the tumours. The results indicate that
reduction in tumour blood ﬂow and tumour oxygenation correlate
with extensive tumour necrosis and induction of apoptosis of the
tumours treated by electrochemotherapy with cisplatin. The data
support the evidence that the antitumour effectiveness of electro-
chemotherapy is not only due to increased drug delivery to the
cells, but also to anti-vascular effect of electrochemotherapy, which
results in reduced tumour blood ﬂow and oxygenation.
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